RionTM, a clinical-stage regenerative medicine company, is focused on developing innovative exosome therapeutics that are clinically impactful, accessible, and practical for any patient. Rion has developed Purified Exosome ProductTM (PEPTM), an innovative biologic platform that harnesses the therapeutic power of exosomes as a truly shelf-stable allogeneic regenerative medicine. PEP is the foundation of Rion’s therapeutic programs, designed to treat a range of indications where tissue regeneration is needed. The company is currently evaluating PEP for the treatment of wound healing, cardiovascular disease, and pelvic floor disorders.
Rion’s co-founders, Drs. Andre Terzic and Atta Behfar, are leaders in the field of regenerative medicine. They made the initial discoveries behind PEP—the result of two decades of preclinical and clinical research in stem cell therapy. Rion was established in 2017 from the Mayo Clinic Employee Entrepreneurial Program and has exclusive worldwide rights from Mayo Clinic to develop and commercialize PEP. The company continues to develop a strong intellectual property portfolio for broad and foundational protection of PEP technology and applications. Rion is backed by extensive scientific, clinical, and regulatory expertise.
In mid-2022, Rion formed a scientific and medical advisory board of experienced professionals with expertise in biologics, cellular-based therapies, manufacturing, and production of human-derived products. We are pleased to announce two of our founding advisory board members.